FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Valk

Research Profile

Disorders

Procedures

Physiology

Living Beings

Genes & Molecular Sequences

Proto-Oncogenes

Phenomena

Virus Integration

Chemicals & Drugs

Devices

Oligonucleotide Array Sequence Analysis

Concepts & Ideas

Survival Analysis

Co-author Network

Publications

TOP 3
Renée Beekman; Peter J M Valk; Marijke Valkhof; Paulette van Strien; Ivo P Touw
Prevalence of a new auto-activating colony stimulating factor 3 receptor mutation (CSF3R-T595I) in acute myeloid leukemia and severe congenital neutropenia.
Mathijs A Sanders; Peter J M Valk
The evolving molecular genetic landscape in acute myeloid leukaemia.
Zejuan Li; Paul P Liu; Bob Löwenberg; Richard Morgan; Mary Beth Neilly; Haomin Ren; Janet D Rowley; Peter J M Valk; Chong-Zhi Wang; Chun-Su Yuan; Zhiyu Zhang; Ping Chen; Ruud Delwel; Konstanze Döhner; Abdel G Elkahloun; Chunjiang He; Gia-Ming Hong; Hao Huang; Xi Jiang; Rejani B Kunjamma; Yuanyuan Li; Stephen Arnovitz; Lars Bullinger; Jianjun Chen
PBX3 is an important cofactor of HOXA9 in leukemogenesis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Valk (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Renée Beekman; Peter J M Valk; Marijke Valkhof; Paulette van Strien; Ivo P Touw
Prevalence of a new auto-activating colony stimulating factor 3 receptor mutation (CSF3R-T595I) in acute myeloid leukemia and severe congenital neutropenia.
Haematologica 2013;98(5):e62-3.
2013: Mathijs A Sanders; Peter J M Valk
The evolving molecular genetic landscape in acute myeloid leukaemia.
Current opinion in hematology 2013;20(2):79-85.
2013: Zejuan Li; Paul P Liu; Bob Löwenberg; Richard Morgan; Mary Beth Neilly; Haomin Ren; Janet D Rowley; Peter J M Valk; Chong-Zhi Wang; Chun-Su Yuan; Zhiyu Zhang; Ping Chen; Ruud Delwel; Konstanze Döhner; Abdel G Elkahloun; Chunjiang He; Gia-Ming Hong; Hao Huang; Xi Jiang; Rejani B Kunjamma; Yuanyuan Li; Stephen Arnovitz; Lars Bullinger; Jianjun Chen
PBX3 is an important cofactor of HOXA9 in leukemogenesis.
Blood 2013;121(8):1422-31.
2013: Stefan Gröschel; Marije Havermans; Jürgen Krauter; Michael W M Kühn; Bob Löwenberg; Michael Lübbert; Gert J Ossenkoppele; Thomas Pabst; Veronika Rockova; Brigitte Schlegelberger; Richard F Schlenk; Ingo G H Schmidt-Wolf; Gerrit J Schuurhuis; Veronica Teleanu; Peter J M Valk; Peter Vandenberghe; Edo Vellenga; Leo F Verdonck; Gregor Verhoef; Hartmut Döhner; Konstanze Döhner; Karina Eiwen; Jan Engelmann; Claudia Erpelinck; Arnold Ganser; Ulrich Germing; Mario Bargetzi; Berna Beverloo; Ruud Delwel
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(1):95-103.
2012: John Anto Pulikkan; Peter J M Valk; Liting Xue; Lihua Julie Zhu; Saman Abbas; Paul Bradley; Ya-Huei Kuo; Sean F. Landrette; Dmitri Madera; Lucio H Castilla
Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
Blood 2012;120(4):868-79.
2012: Ana Flávia Tibúrcio Ribeiro; Veronika Rockova; Mathijs Sanders; Peter J M Valk; Annelieke Zeilemaker; Claudia Erpelinck-Verschueren; Maria E Figueroa; Bob Löwenberg; Ari Melnick; Marta Pratcorona; Saman Abbas; Ruud Delwel
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
Blood 2012;119(24):5824-31.
2012: Renée Beekman; Lianne Broeders; Wendy M Geertsma-Kleinekoort; Jurgen Haanstra; Bob Löwenberg; Mathijs A Sanders; Peter J M Valk; Marijke Valkhof; Paulette M H van Strien; Anjo J P Veerman; Roel G W Verhaak; Ivo P Touw
Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.
Blood 2012;119(22):5071-7.
2012: Zejuan Li; Paul P Liu; Bob Lowenberg; Yves lussier; Kati Maharry; Guido Marcucci; Mary Beth Neilly; Colles Price; Michael D Radmacher; Janet D Rowley; Peter J M Valk; Xinan Yang; Yanming Zhang; Zhiyu Zhang; Ping Chen; Ruud Delwel; Konstanze Dohner; Abdel Elkahloun; Chunjiang He; Miao He; Hao Huang; Xi Jiang; Richard A Larson; Michelle M Le Beau; Yuanyuan Li; Stephen Arnovitz; Clara D Bloomfield; Lars Bullinger; Michael A Caligiuri; Jianjun Chen
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
Blood 2012;119(10):2314-24.
2012: Marta Pratcorona; Mathijs A Sanders; Annelieke Zeilemakers; Saman Abbas; Claudia A J Erpelinck-Verschueren; François G Kavelaars; Jasper E Koenders; Bob Löwenberg; Peter J M Valk
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
Haematologica 2012;97(3):388-92.
2012: Altuna Akalin; C David Allis; Debabrata Biswas; Jennifer Busuttil; Ruud Delwel; Hugo F Fernandez; Francine E Garrett-Bakelman; Jay L Hess; Yongsheng Huang; Irina Khrebtukova; Matthias Kormaksson; Bob Löwenberg; Christopher E Mason; Ari Melnick; Thomas A Milne; Elisabeth Paietta; Robert G Roeder; Gary P Schroth; Martin S Tallman; Peter J M Valk; Lu Zhang; Maria E Figueroa
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.
PLoS genetics 2012;8(6):e1002781.
2012: Zejuan Li; Paul P Liu; Bob Lowenberg; Jun Lu; James C Mulloy; Mary Beth Neilly; Chen Shen; Peter J M Valk; James Vardiman; Yungui Wang; Minjie Wei; Mark Wunderlich; Nancy J Zeleznik-Le; Jiwang Zhang; Jun Zhang; Zhiyu Zhang; Ping Chen; Ruud Delwel; Abdel Elkahloun; Chunjiang He; Miao He; Hao Huang; Elizabeth Hyjek; Xi Jiang; Jie Jin; Michelle M Le Beau; Yuanyuan Li; Stephen Arnovitz; Donglin Cao; Jianjun Chen
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.
Nature communications 2012;3():688.
2011: Sylvie M Noordermeer; Mathijs A Sanders; Evelyn Tönnissen; Peter J M Valk; Adrian van der Heijden; Lars Bullinger; Konstanze Döhner; Christian Gilissen; Joop H Jansen; Bert A van der Reijden
High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9-positive patients.
Blood 2011;118(20):5613-21.
2011: Su Ming Sun; Peter J M Valk; Bob Löwenberg; André C Bijkerk; Rik A Brooimans; Menno K Dijkstra; Stefan J Erkeland; Mojca Jongen-Lavrencic
Transition of highly specific microRNA expression patterns in association with discrete maturation stages of human granulopoiesis.
British journal of haematology 2011;155(3):395-8.
2011: Iris H I M Hollink; Gert-Jan J L Kaspers; Jenny E Kuipers; Rob Pieters; Marta Pratcorona; Dirk Reinhardt; Edwin Sonneveld; Jan Trka; Peter J M Valk; Marry M van den Heuvel-Eibrink; Janneke F van Galen; Martin Zimmermann; Saman Abbas; Susan T C J M Arentsen-Peters; Andre Baruchel; Berna Beverloo; Ursula Creutzig; Christian M Zwaan
NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.
Blood 2011;118(13):3645-56.
2011: Veronika Rockova; Wim L J van Putten; Bas J Wouters; Saman Abbas; Berna Beverloo; Ruud Delwel; Claudia Erpelinck; Bob Löwenberg; Peter J M Valk
Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers.
Blood 2011;118(4):1069-76.
2011: Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Martin Zimmermann; Justine K Peeters; Peter J M Valk; Brian Balgobind; Edwin Sonneveld; Gertjan J L Kaspers; Eveline S J M de Bont; Jan Trka; Andre Baruchel; Ursula Creutzig; Rob Pieters; Dirk Reinhardt; Christian M Zwaan
Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
Haematologica 2011;96(3):384-92.
2011: Erdogan Taskesen; Lars Bullinger; Andrea Corbacioglu; Mathijs A Sanders; Claudia Erpelinck; Bas J Wouters; Sonja C van der Poel-van de Luytgaarde; Frederik Damm; Jürgen Krauter; Arnold Ganser; Richard F Schlenk; Bob Löwenberg; Ruud Delwel; Hartmut Döhner; Peter J M Valk; Konstanze Döhner
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.
Blood 2011;117(8):2469-75.
2011: Sanne Lugthart; Maria E Figueroa; Eric Bindels; Lucy Skrabanek; Peter J M Valk; Yushan Li; Stefan Meyer; Claudia Erpelinck-Verschueren; John M Greally; Bob Löwenberg; Ari Melnick; Ruud Delwel
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
Blood 2011;117(1):234-41.
2011: Renée Beekman; Stefan J Erkeland; Bob Löwenberg; Justine K Peeters; Veronika Rockova; Erdogan Taskesen; Peter J M Valk; Marijke Valkhof; Ivo P Touw
Retroviral integration mutagenesis in mice and comparative analysis in human AML identify reduced PTP4A3 expression as a prognostic indicator.
PloS one 2011;6(10):e26537.
2011: Karishma K Palande; Renee Beekman; Lotte E van der Meeren; Berna Beverloo; Peter J M Valk; Ivo P Touw
The antioxidant protein peroxiredoxin 4 is epigenetically down regulated in acute promyelocytic leukemia.
PloS one 2011;6(1):e16340.
2010: Wendy Deenik; Bronno van der Holt; Jeroen J W M Janssen; Isabel W T Chu; Peter J M Valk; Gert Ossenkoppele; Ilse P van der Heiden; Pieter Sonneveld; Ron van Schaik; Jan J Cornelissen
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.
Blood 2010;116(26):6144-5; author reply 6145-6.
2010: Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig Thompson; Ross L Levine; Ari Melnick
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Cancer cell 2010;18(6):553-67.
2010: Hidde L A Posthuma; Radek C Skoda; Frank A Jacob; Anthonie P C van der Maas; Peter J M Valk; Eduardus F M Posthuma
Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis.
Blood 2010;116(17):3375-6.
2010: J J W M Janssen; Fedor Denkers; Peter J M Valk; Jan J Cornelissen; Gerrit J Schuurhuis; Gert Ossenkoppele
Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells.
Haematologica 2010;95(6):1036-7.
2010: Wendy Deenik; J J W M Janssen; Bronno van der Holt; Gregor Verhoef; Willem M Smit; Marie José Kersten; Simon M G J Daenen; Leo F Verdonck; Augustin Ferrant; A V M B Schattenberg; Pieter Sonneveld; Marinus van Marwijk Kooy; Shulamiet Wittebol; Roelof Willemze; Pierre W Wijermans; Berna Beverloo; Bob Löwenberg; Peter J M Valk; Gert Ossenkoppele; Jan J Cornelissen
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.
Haematologica 2010;95(6):914-21.
2010: Stefan Gröschel; Sanne Lugthart; Richard F Schlenk; Peter J M Valk; Karina Eiwen; Chantal Goudswaard; Wim J L van Putten; Sabine Kayser; Leo F Verdonck; Michael Lübbert; Gert-Jan Ossenkoppele; Ulrich Germing; Ingo Schmidt-Wolf; Brigitte Schlegelberger; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Bob Löwenberg; Konstanze Döhner; Ruud Delwel
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(12):2101-7.
2010: S Abbas; Claudia A J Erpelinck-Verschueren; Chantal S Goudswaard; Bob Löwenberg; Peter J M Valk
Mutant Wilms' tumor 1 (WT1) mRNA with premature termination codons in acute myeloid leukemia (AML) is sensitive to nonsense-mediated RNA decay (NMD).
Leukemia 2010;24(3):660-3.
2010: Maria E Figueroa; Sanne Lugthart; Yushan Li; Claudia Erpelinck-Verschueren; Xutao Deng; Paul J Christos; Elizabeth Schifano; James Booth; Wim van Putten; Lucy Skrabanek; Fabien Campagne; Madhu Mazumdar; John M Greally; Peter J M Valk; Bob Löwenberg; Ruud Delwel; Ari Melnick
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.
Cancer cell 2010;17(1):13-27.
2010: Roel G W Verhaak; Peter J M Valk
Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia.
Cancer treatment and research 2010;145():67-83.
2009: Bas J Wouters; Bob Löwenberg; Claudia A J Erpelinck-Verschueren; Wim L J van Putten; Peter J M Valk; Ruud Delwel
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.
Blood 2009;113(13):3088-91.
2009: Maria E Figueroa; Bas J Wouters; Lucy Skrabanek; Jacob Glass; Yushan Li; Claudia A J Erpelinck-Verschueren; Anton W Langerak; Bob Löwenberg; Melissa Fazzari; John M Greally; Peter J M Valk; Ari Melnick; Ruud Delwel
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features.
Blood 2009;113(12):2795-804.
2009: Roel G W Verhaak; Bas J Wouters; Claudia A J Erpelinck; Saman Abbas; Berna Beverloo; Sanne Lugthart; Bob Löwenberg; Ruud Delwel; Peter J M Valk
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling.
Haematologica 2009;94(1):131-4.
2008: Mojca Jongen-Lavrencic; Su Ming Sun; Menno K Dijkstra; Peter J M Valk; Bob Löwenberg
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.
Blood 2008;111(10):5078-85.
2008: Sanne Lugthart; Ellen van Drunen; Yvette van Norden; Antoinette van Hoven; Claudia Erpelinck; Peter J M Valk; Berna Beverloo; Bob Löwenberg; Ruud Delwel
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Blood 2008;111(8):4329-37.
2008: Mathijs A Sanders; Roel G W Verhaak; Wendy M C Geertsma-Kleinekoort; Saman Abbas; Sebastiaan Horsman; Peter van der Spek; Bob Löwenberg; Peter J M Valk
SNPExpress: integrated visualization of genome-wide genotypes, copy numbers and gene expression levels.
BMC genomics 2008;9():41.
2007: Bas J Wouters; Meritxell Alberich Jordà; Karen Keeshan; Irene Louwers; Claudia A J Erpelinck-Verschueren; Dennis Tielemans; Anton Langerak; Yiping He; Yumi Yashiro-ohtani; Pu Zhang; Christopher J Hetherington; Roel G W Verhaak; Peter J M Valk; Bob Löwenberg; Daniel G Tenen; Warren S Pear; Ruud Delwel
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.
Blood 2007;110(10):3706-14.
2007: D C Gilby; A C Goodeve; Peter R Winship; Peter J M Valk; Ruud Delwel; J T Reilly
Gene structure, expression profiling and mutation analysis of the tumour suppressor SHIP1 in Caucasian acute myeloid leukaemia.
Leukemia 2007;21(11):2390-3.
2007: Bas J Wouters; Mathijs A Sanders; S Lugthart; W M C Geertsma-Kleinekoort; Ellen van Drunen; Berna Beverloo; Bob Löwenberg; Peter J M Valk; Ruud Delwel
Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia.
Leukemia 2007;21(11):2382-4.
2007: Bas J Wouters; Irene Louwers; Peter J M Valk; Bob Löwenberg; Ruud Delwel
A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML.
Blood 2007;109(1):389-90.
2006: Susan A Heilman; Ya-Huei Kuo; Chantal S Goudswaard; Peter J M Valk; Lucio H Castilla
Cbfbeta reduces Cbfbeta-SMMHC-associated acute myeloid leukemia in mice.
Cancer research 2006;66(23):11214-8.
2006: Karen Keeshan; Yiping He; Bas J Wouters; Olga Shestova; Lanwei Xu; Hong Sai; Carlos G Rodriguez; Ivan P Maillard; John W Tobias; Peter J M Valk; Martin Carroll; Jon C Aster; Ruud Delwel; Warren S Pear
Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia.
Cancer cell 2006;10(5):401-11.
2006: Ulrich Steidl; Frank Rosenbauer; Roel G W Verhaak; Xuesong Gu; Alexander Ebralidze; Hasan H Otu; Steffen Klippel; Christian Steidl; Ingmar Bruns; Daniel B Costa; Katharina Wagner; Manuel Aivado; Guido Kobbe; Peter J M Valk; Emmanuelle Passegué; Towia Libermann; Ruud Delwel; Daniel G Tenen
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells.
Nature genetics 2006;38(11):1269-77.
2006: Joke G Boonstra; Kirsten van Lom; Anton Langerak; Wilfried J Graveland; Peter J M Valk; Jaco Kraan; Mars B van 't Veer; Jan W Gratama
CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression.
Cytometry. Part B, Clinical cytometry 2006;70(3):136-41.
2006: Stefan J Erkeland; Roel G W Verhaak; Peter J M Valk; Ruud Delwel; Bob Löwenberg; Ivo P Touw
Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia.
Cancer research 2006;66(2):622-6.
2006: Roel G W Verhaak; Mathijs A Sanders; Maarten A Bijl; Ruud Delwel; Sebastiaan Horsman; Michael J Moorhouse; Peter van der Spek; Bob Löwenberg; Peter J M Valk
HeatMapper: powerful combined visualization of gene expression profile correlations, genotypes, phenotypes and sample characteristics.
BMC bioinformatics 2006;7():337.
2006: Roel G W Verhaak; Frank Staal; Peter J M Valk; Bob Lowenberg; Marcel J T Reinders; Dick de Ridder
The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies.
BMC bioinformatics 2006;7():105.
2006: Mars B van't Veer; Anne M Brooijmans; Anton Langerak; Brenda Verhaaf; Chantal S Goudswaard; Wilfried J Graveland; Kirsten van Lom; Peter J M Valk
The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia.
Haematologica 2006;91(1):56-63.
2005: Roel G W Verhaak; Chantal S Goudswaard; Wim L J van Putten; Maarten A Bijl; Mathijs A Sanders; Wendy Hugens; André G Uitterlinden; Claudia Erpelinck; Ruud Delwel; Bob Löwenberg; Peter J M Valk
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
Blood 2005;106(12):3747-54.
2005: Eric van den Akker; Yolanda Vankan-Berkhoudt; Peter J M Valk; Bob Löwenberg; Ruud Delwel
The common viral insertion site Evi12 is located in the 5'-noncoding region of Gnn, a novel gene with enhanced expression in two subclasses of human acute myeloid leukemia.
Journal of virology 2005;79(9):5249-58.
2005: James C Mulloy; Vlaidmir Jankovic; Mark Wunderlich; Ruud Delwel; Jörg Cammenga; Ondrej Krejci; Hui Zhao; Peter J M Valk; Bob Lowenberg; Stephen D Nimer
AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(11):4016-21.
2005: Peter J M Valk; Ruud Delwel; Bob Löwenberg
Gene expression profiling in acute myeloid leukemia.
Current opinion in hematology 2005;12(1):76-81.
2004: Peter J M Valk; Roel G W Verhaak; M Antoinette Beijen; Claudia Erpelinck; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Judith M Boer; Berna Beverloo; Michael J Moorhouse; Peter van der Spek; Bob Löwenberg; Ruud Delwel
Prognostically useful gene-expression profiles in acute myeloid leukemia.
The New England journal of medicine 2004;350(16):1617-28.
2004: Peter J M Valk; David T Bowen; Marion E Frew; Anne C Goodeve; Bob Löwenberg; John T Reilly
Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16).
Haematologica 2004;89(1):106.
2003: Leendert H J Looijenga; Hubert P J C de Leeuw; Monique van Oorschot; Ruud van Gurp; hans stoop; Ad J M Gillis; Carlos A de Gouveia Brazao; R F A Weber; Wim J Kirkels; Thamar B van Dijk; Marieke von Lindern; Peter J M Valk; Geczy Lajos; Edit Olah; Jahn M Nesland; Sophie D Fosså; J Wolter Oosterhuis
Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors.
Cancer research 2003;63(22):7674-8.
2003: Rory S Care; Peter J M Valk; Anne C Goodeve; Faisel M Abu-Duhier; Wendy M C Geertsma-Kleinekoort; Gill A Wilson; Mamdooh A Gari; Ian R Peake; Bob Löwenberg; John T Reilly
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias.
British journal of haematology 2003;121(5):775-7.
2003: Meritxell Alberich Jorda; Nazik Rayman; Peter J M Valk; Eva De Wee; Ruud Delwel
Identification, characterization, and function of a novel oncogene: the peripheral cannabinoid receptor Cb2.
Annals of the New York Academy of Sciences 2003;996():10-6.
2003: Stefan J Erkeland; Marijke Valkhof; Claudia Heijmans-Antonissen; Ruud Delwel; Peter J M Valk; Mirjam H A Hermans; Ivo P Touw
The gene encoding the transcriptional regulator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation.
Blood 2003;101(3):1111-7.
2003: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Claudia Erpelinck; Wim L J van Putten; Peter J M Valk; Sonja van der Poel-van de Luytgaarde; Ronald Hack; Rosalyn Slater; Elisabeth M E Smit; Berna Beverloo; Gregor Verhoef; Leo F Verdonck; Gert Ossenkoppele; Pieter Sonneveld; Georgine E De Greef; Bob Löwenberg; Ruud Delwel
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Blood 2003;101(3):837-45.
2003: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Claudia Erpelinck; Joost Meijer; Susanna van Oosterhoud; Wim L J van Putten; Peter J M Valk; H Berna Beverloo; Daniel G Tenen; Bob Löwenberg; Ruud Delwel
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
The hematology journal : the official journal of the European Haematology Association / EHA 2003;4(1):31-40.
2002: Marieke Joosten; Yolanda Vankan-Berkhoudt; Marjolein Tas; Monja Lunghi; Yvonne Bastiaansen-Jenniskens; Evan Parganas; Peter J M Valk; Bob Löwenberg; Eric van den Akker; Ruud Delwel
Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites.
Oncogene 2002;21(47):7247-55.
2002: Bert A van der Reijden; Annet Simons; Erna Luiten; Sonja C van der Poel; Pauline E Hogenbirk; Evelyn Tönnissen; Peter J M Valk; Bob Löwenberg; Georgine E De Greef; Martijn H Breuning; Joop H Jansen
Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion.
British journal of haematology 2002;118(2):411-8.
2002: Meritxell Alberich Jordà; Sandra E Verbakel; Peter J M Valk; Yolanda Vankan-Berkhoudt; Mauro Maccarrone; Allessandro Finazzi-Agrò; Bob Löwenberg; Ruud Delwel
Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol.
Blood 2002;99(8):2786-93.
2002: Marieke Joosten; Peter J M Valk; Meritxell Alberich Jordà; Yolanda Vankan-Berkhoudt; Sandra E Verbakel; Marion van den Broek; Antoinette Beijen; Bob Löwenberg; Ruud Delwel
Leukemic predisposition of pSca-1/Cb2 transgenic mice.
Experimental hematology 2002;30(2):142-9.
2000: Marieke Joosten; Peter J M Valk; Y Vankan; NJ de Both; Bob Löwenberg; Ruud Delwel
Phenotyping of Evi1, Evi11/Cb2, and Evi12 transformed leukemias isolated from a novel panel of cas-Br-M murine leukemia virus-infected mice.
Virology 2000;268(2):308-18.
2000: Peter J M Valk; Sandra E Verbakel; Marieke von Lindern; Bob Löwenberg; Ruud Delwel
Enhancement of erythropoietin-stimulated cell proliferation by Anandamide correlates with increased activation of the mitogen-activated protein kinases ERK1 and ERK2.
The hematology journal : the official journal of the European Haematology Association / EHA 2000;1(4):254-63.
1999: Peter J M Valk; Y Vankan; Marieke Joosten; N A Jenkins; N G Copeland; Bob Löwenberg; Ruud Delwel
Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincide with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2.
Journal of virology 1999;73(5):3595-602.
1998: Peter J M Valk; Ruud Delwel
The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis.
Leukemia & lymphoma 1998;32(1-2):29-43.
1997: Peter J M Valk; Marieke Joosten; Y Vankan; Bob Löwenberg; Ruud Delwel
A rapid RT-PCR based method to isolate complementary DNA fragments flanking retrovirus integration sites.
Nucleic acids research 1997;25(21):4419-21.
1997: Peter J M Valk; S Hol; Y Vankan; J N Ihle; D Askew; N A Jenkins; D J Gilbert; N G Copeland; NJ de Both; Bob Löwenberg; Ruud Delwel
The genes encoding the peripheral cannabinoid receptor and alpha-L-fucosidase are located near a newly identified common virus integration site, Evi11.
Journal of virology 1997;71(9):6796-804.
1997: Peter J M Valk; Sandra E Verbakel; Y Vankan; S Hol; S Mancham; Rob E Ploemacher; AE Mayen; Bob Löwenberg; Ruud Delwel
Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells.
Blood 1997;90(4):1448-57.